Optimist Retirement Group LLC Invests $220,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Optimist Retirement Group LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,391 shares of the biotechnology company’s stock, valued at approximately $220,000.

Several other large investors also recently modified their holdings of the stock. Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after buying an additional 75 shares during the period. GAMMA Investing LLC grew its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after buying an additional 120 shares during the period. WCM Investment Management LLC grew its position in shares of Sarepta Therapeutics by 2.3% during the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after buying an additional 142 shares during the period. Finally, Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. The disclosure for this purchase can be found here. Insiders have sold 52,801 shares of company stock worth $8,399,586 in the last ninety days. Company insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Cantor Fitzgerald reduced their price target on shares of Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. BMO Capital Markets lifted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and reduced their price target for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Sarepta Therapeutics in a research report on Friday, September 6th. Three analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Trading Down 0.5 %

NASDAQ SRPT opened at $125.01 on Thursday. The stock has a market capitalization of $11.82 billion, a price-to-earnings ratio of 1,136.45 and a beta of 0.81. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The business’s fifty day moving average is $138.75 and its 200-day moving average is $132.67.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.27) EPS. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.